Skip to main content
. 2023 May 15;5(3):otad026. doi: 10.1093/crocol/otad026

Figure 3:

Figure 3:

Proportion of patients stratified by their pretreatment vitamin D status and outcomes to anti-TNF at (A) week 14 and (B) week 54. Infliximab-treated patients on the left panel, and adalimumab-treated patients on the right panel. The number of patients experiencing each outcome is annotated in the plot, with the proportion in brackets (%). PNR, primary non-response.